Skip to main content

Advertisement

SpringerLink
Log in

Systemic inflammatory response index is a prognostic biomarker in unresectable pancreatic adenocarcinoma and identifies patients for more intensive treatment

  • original report
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Background

The link between systemic inflammation and pancreatic cancer is widely accepted. The systemic inflammatory response index (SIRI), based on peripheral neutrophil, monocyte, and lymphocyte counts, emerged recently as a prognostic tool in several types of cancer. The aim of this study is to evaluate the prognostic and predictive value of baseline SIRI in unresectable pancreatic cancer.

Materials and methods

Retrospective analysis of 112 patients with unresectable pancreatic ductal adenocarcinoma (PDAC) followed between 2016 and 2021. Receiver operating characteristic (ROC) curve analysis was used to obtain the optimal SIRI cut-off value, which was set at 1.34.

Results

Univariate analysis showed that SIRI ≥ 1.34 was associated with significantly lower overall survival (OS; p < 0.0001). Multivariate analyses confirmed that SIRI is an independent prognostic factor regardless of first-line chemotherapy regimen (p < 0.0001; hazard ratio [HR] 0.363; 95% confidence interval [CI] 0.223–0.566). Also, patients with SIRI ≥ 1.34 undergoing platinum-based treatment had significantly longer OS than those treated with gemcitabine-based regimens (p = 0.002).

Conclusion

Our study suggests that SIRI is able to predict OS in patients with PDAC. Patients with high SIRI values treated with platinum-based chemotherapy achieved longer OS than those treated with gemcitabine-based regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Orth M, Metzger P, Gerum S, et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019;14(1):1–20. https://doi.org/10.1186/s13014-019-1345-6.

    Article  Google Scholar 

  2. Costa PM, Marinho RT, Cortez-Pinto H, et al. Twenty-five years of increasing mortality from pancreatic cancer in Portugal. Pancreas. 2020;43(1):e2–e3.

    Article  Google Scholar 

  3. Gao Y, Wang WJ, Zhi Q, et al. Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer. Oncotarget. 2017;8(51):88835–44. https://doi.org/10.18632/oncotarget.21340.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Pacheco-Barcia V, Mondéjar Solís R, France T, et al. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. Pancreatology. 2020;20(2):254–64. https://doi.org/10.1016/j.pan.2019.12.010.

    Article  CAS  PubMed  Google Scholar 

  5. Chen Y, Shao Z, Chen W, et al. A varying-coefficient cox model for the effect of CA19‑9 kinetics on overall survival in patients with advanced pancreatic cancer. Oncotarget. 2017;8(18):29925–34. https://doi.org/10.18632/oncotarget.15557.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19‑9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence-based appraisal. J Gastrointest Oncol. 2012;3(2):105–19. https://doi.org/10.3978/j.issn.2078-6891.2011.021.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hoshimoto S, Hishinuma S, Shirakawa H, et al. Validation and clinical usefulness of pre- and postoperative systemic inflammatory parameters as prognostic markers in patients with potentially resectable pancreatic cancer. Pancreatology. 2020;20(2):239–46. https://doi.org/10.1016/j.pan.2019.12.004.

    Article  PubMed  Google Scholar 

  8. Chen Y, Jiang W, Xi D, et al. Development and validation of nomogram based on SIRI for predicting the clinical outcome in patients with nasopharyngeal carcinomas. J Investig Med. 2019;67(3):691–8. https://doi.org/10.1136/jim-2018-000801.

    Article  PubMed  Google Scholar 

  9. Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–67. https://doi.org/10.1002/cncr.30057.

    Article  PubMed  Google Scholar 

  10. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. https://doi.org/10.1056/NEJMoa1304369.

    Article  CAS  Google Scholar 

  11. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. https://doi.org/10.1056/NEJMoa1011923.

    Article  CAS  PubMed  Google Scholar 

  12. Virchow R. Cellular pathology. As based upon physiological and pathological histology. Lecture XVI—Atheromatous affection of arteries. 1858. Nutr Rev. 1989;47(1):23–5. https://doi.org/10.1111/j.1753-4887.1989.tb02747.x.

    Article  CAS  PubMed  Google Scholar 

  13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.

    Article  CAS  PubMed  Google Scholar 

  14. Weizman N, Krelin Y, Shabtay-Orbach A, et al. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene. 2014;33(29):3812–9. https://doi.org/10.1038/onc.2013.357.

    Article  CAS  PubMed  Google Scholar 

  15. Azab B, Bhatt VR, Phookan J, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19(1):217–24. https://doi.org/10.1245/s10434-011-1814-0.

    Article  PubMed  Google Scholar 

  16. Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91(3):181–4. https://doi.org/10.1002/jso.20329.

    Article  CAS  PubMed  Google Scholar 

  17. Clark EJ, Connor S, Taylor MA, et al. Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB. 2007;9(6):456–60. https://doi.org/10.1080/13651820701774891.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Shirai Y, Shiba H, Sakamoto T, et al. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Surgery. 2015;158(2):360–5. https://doi.org/10.1016/j.surg.2015.03.043.

    Article  PubMed  Google Scholar 

  19. Li S, Xu H, Wang W, et al. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Cancer Manag Res. 2019;11:3327–37. https://doi.org/10.2147/CMAR.S197911.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

All authors contributed significantly to this article.

Funding

This research did not receive any grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Centro Hospitalar Universitário Lisboa Norte, Av. Prof. Egas Moniz MB, 1649-028, Lisboa, Portugal

    Sara Dâmaso MD, Rita Paiva MD, Inês Pinho MD, Miguel Esperança-Martins MD, Raquel Lopes Brás MD, Cecília Melo Alvim MD, António Quintela MD, Ana Lúcia Costa MD & Luís Costa MD

  2. Translational Oncobiology Lab, Instituto de Medicina Molecular João Lobo Antunes, Lisboa, Portugal

    Luís Costa MD

Authors
  1. Sara Dâmaso MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rita Paiva MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Inês Pinho MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miguel Esperança-Martins MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raquel Lopes Brás MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cecília Melo Alvim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. António Quintela MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ana Lúcia Costa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Luís Costa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sara Dâmaso MD.

Ethics declarations

Conflict of interest

S. Dâmaso, R. Paiva, I. Pinho, M. Esperança-Martins, R. Lopes Brás, C. Melo Alvim, A. Quintela, A. Lúcia Costa and L. Costa declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dâmaso, S., Paiva, R., Pinho, I. et al. Systemic inflammatory response index is a prognostic biomarker in unresectable pancreatic adenocarcinoma and identifies patients for more intensive treatment. memo 15, 246–252 (2022). https://doi.org/10.1007/s12254-022-00829-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-022-00829-2

Keywords

Search

Navigation